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Abstract
Continued growth in the cell therapy industry and commercialization of cell therapies that successfully advance through
clinical trials has led to increased awareness around the need for specialized and complex materials utilized in their man-
ufacture. Ancillary materials (AMs) are components or reagents used during the manufacture of cell therapy products but
are not intended to be part of the final products. Commonly, there are limitations in the availability of clinical-grade re-
agents used as AMs. Furthermore, AMs may affect the efficacy of the cell product and subsequent safety of the cell therapy
for the patient. As such, AMs must be carefully selected and appropriately qualified during the cell therapy development
process. However, the ongoing evolution of cell therapy research, limited number of clinical trials and registered cell therapy
products results in the current absence of specific regulations governing the composition, compliance, and qualification of
AMs often leads to confusion by suppliers and users in this field. Here we provide an overview and interpretation of the
existing global framework surrounding AM use and investigate some common misunderstandings within the industry, with
the aim of facilitating the appropriate selection and qualification of AMs.The key message we wish to emphasize is that in
order to most effectively mitigate risk around cell therapy development and patient safety, users must work with their sup-
pliers and regulators to qualify each AM to assess source, purity, identity, safety, and suitability in a given application.
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Introduction
Interest continues to grow in the development and
commercialization of cellular therapies because of their
potential to resolve a large number of unmet clinical
indications [1,2]. Consequently, as new therapies
advance through clinical trials, there is increasing scru-
tiny of the materials and processes used in the
manufacture of the intended cell therapy product. A
wide variety of starting materials may be used in the
manufacturing process, some of which are integral to
the final product, and in some cases, contribute to its
composition or are found in the final cell product as
active ingredients or as excipients.Whereby some ma-
terials used with the manufacturing process are
ancillary materials, which, by definition, are compo-
nents, reagents or materials used during manufacture
that exert an effect on the cell product but are not in-
tended to be part of the final cell product. It should
be noted that the term ancillary material (AM) is not
globally recognized by regulators and is commonly re-
ferred to as raw material in some jurisdictions, such
as in Europe; however, for the sake of clarity, this paper
will use the term AM throughout to describe such ma-
terials. Examples of AMs include but are not limited
to: cell separation reagents, cell culture media,
Correspondence: Jennifer Solomon, PhD, Suite 500, 1618 Station Street,Vancouver, BC, CanadaV6A 1B6. E-mail: jennifer.solomon@stemcell.com
(Received 3 February 2015; accepted 21 September 2015)
ISSN 1465-3249 Copyright © 2015 International Society for Cellular Therapy. Published by Elsevier Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
http://dx.doi.org/10.1016/j.jcyt.2015.09.010
Cytotherapy, 2016; 18: 1–12
cryopreservation agents and disposables such as
plasticware and bioprocessing bags. Many grades
and compositions of AMs exist, and typically these
are not approved or intended for clinical administra-
tion or use (eg, are labeled as “research use only”).
Because an AM does come in contact with cells des-
tined for clinical administration, the quality of the AM
used can affect the safety, potency and purity of the
cell product. As such, the long-term appropriateness
of reagents and materials for use as AMs in a clini-
cal setting must be considered under a phased and
risk-based approach at each stage along the develop-
ment process of a cellular therapeutic and evaluated
on the basis of various criteria, including but not limited
to suitability in the given application, composition, com-
pliance, cost, availability and. ultimately, risk to patient
safety.
Currently, no AM-specific regulations exist in
worldwide regulatory frameworks. A growing number
of guidance documents reference AM use from several
national and international organizations [3–6], and,
although these organizations provide a framework
for strategies to control AMs, raw materials, compo-
nents and starting materials, they do not precisely
define the regulatory or quality requirements for AMs.
More specifically, regulators provide limited guid-
ance to cell therapy manufacturers (herein referred
to as AM users) surrounding compliance require-
ments, generation and execution of qualification
programs and the accountabilities of AM users com-
pared with AM suppliers along development paths.
Furthermore, AM suppliers do not consistently clas-
sify and name reagents intended for use as AMs,
leading to further challenges to compliance. As a
result, there is much confusion and mismatched ex-
pectations pertaining to the requirements for both
users and suppliers. The intent of this paper is to
bring further awareness to existing regulatory guid-
ance and assist in clarifying some common
misunderstandings as they relate to AMs. Moreover,
this paper should serve as a resource to aid in the
process of qualification and final selection of AMs
for use in cellular therapy applications and ultimate-
ly to facilitate the development and commercialization
of cellular therapies worldwide. Although the scope
of this paper is limited, we will provide a starting
point for communication between AM users, suppli-
ers and regulators by defining commonly observed
terminology, highlighting current applicable regula-
tions and key guidance references, defining compliance
and how it relates to AM use at various stages of
cellular therapy development and, finally, outlining
key responsibilities and accountabilities surrounding
AM qualification on the basis of our combined ex-
periences. We anticipate that this paper will be the
first of a series that evaluate and help to establish
standards for AM requirements globally.
Terminology
The terminology and quality or compliance claims used
to describe AMs for cellular therapies can often be con-
fusing because of inconsistent classification, naming
or labeling for intended use. Very few of the more
common terms are aligned across industry or region,
which makes it exceedingly difficult for end-users to
confidently select AMs at critical stages of the devel-
opment process. In some instances, the terminology
may simply be a variation in labeling or marketing tech-
niques between different manufacturers of similar
products. Such is the case with laboratory-grade and
research-grade terminology frequently used to de-
scribe the same AM offered by separate suppliers.
However, more frequent misunderstanding arises
around current GoodManufacturing Practice (cGMP)
labeling, such as products labeled as GMP, cGMP-
compliant, or manufactured under cGMP, the
interpretation of the requirements to label products
as such and the understanding of the intended use (for
example, GMP AMs labeled as research use only).
Other parties have provided some guidance related to
definition of terms in specific regions or as part of in-
dependent initiatives that can be leveraged [7].
However, given the criticality of the components and
processes required to develop cell therapies, it is im-
portant to understand the terminology and highlight
the potential differences as they relate to AMs, and
materials in general, on a more global perspective.
Table 1 defines the more commonly used quality and
regulatory terms that describe AMs used for cell thera-
pies that are based on existing guidances and opinion
within the industry. It is recognized that there are in-
ternational differences and discrepancies that are based
on intended use of the AM (eg, in research versus clin-
ical applications) and that this table does not recognize
all opinions globally, despite the authors’ best efforts.
It is important for AM users to investigate and fully
understand the claims made by suppliers. Because of
the lack of governance and consistency around AM
labeling and naming, it is common that suppliers have
different definitions and interpretations of standard
terms for quality claims. Early and continuous com-
munication between the users and suppliers is critical
to align expectations. Furthermore, it is anticipated
that dialogue between the users and their regulators
will enhance user qualification requirements, and, ul-
timately, hold suppliers accountable for AM labeling
and marketing claims.
However, to further complicate the qualification
process, AM manufacturing processes and formula-
tions are generally considered proprietary, and many
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Table 1. Common quality and regulatory terminology.
Term Meaning
Alternative or
synonymous terms
Ancillary material Materials (active or inert) that come in contact with the cell or tissue product
during manufacturing but are not intended to be part of the final product [1].
Ancillary materials are commonly labeled as “not for use in clinical or diagnostic
procedures” or “for ex vivo use only and not intended for human in vivo
applications.”
Regional differences in terminology exists. Ancillary material is not used by
European regulators, for example; “raw material” is synonymous with this
term in Europe.
Ancillary product
Ancillary reagent
Processing aid
Processing reagent
Raw material (EU)
Reagent
Animal-derived
component–free
(ADCF)
In the context of this paper, “animal” refers to all animals, including humans.
A term used by AM manufacturers to describe products or materials that do not
contain as an ingredient that is either an animal tissue or body fluid or is
isolated or purified from animal tissue or body fluid.
May contain recombinant proteins produced in animal cell lines or by
fermentation processes.
Does not necessarily limit the use of animal-derived components used in the
manufacture of AM raw materials (secondary materials) or materials used
further downstream (tertiary, etc), unless indicated.
Animal component–free
(ACF)
Animal origin–free
(AOF)
Chemically defined A term used by AM manufacturers to describe products or materials that have
known chemical structures (defined by a chemical formula) and high purity,
for example small molecules, salts, carbohydrates, amino acids, fatty acids and
steroids (cholesterol, dexamethasone).This will be evaluated on a case-by-case
basis.
Does not contain proteins or other ingredients with a complex structure.
Ingredients may be synthetic or biologically derived (eg, cholesterol from sheep’s
wool grease).
ACF
Serum-free
Clinical-grade A term used by AM manufacturers to describe products or materials that are
suitable for clinical use, for example, injectable grade. Material shown to be
safe and efficacious for human use through appropriate clinical trials and
regulatory approvals. Usually clinical-grade products are approved as drugs by
regulators, and labeling or product documentation should state sterility and
safety profile.
Suitable for clinical use for a specified intended use only. Clinical-grade AM for
a specific and approved intended use does not mean that the AM is approved
for other “off-label” processing uses without qualification and approval from
the appropriate regulatory agency.
Pharmacopeial-grade
Infusible-grade
Active pharmaceutical
ingredient (API)-grade
Approved for human use
Defined A term used by AM manufacturers to describe products or materials that o not
contain undefined components such as serum, plasma, platelet lysate, tissue
extracts or plant hydrolysates as ingredients.
Ingredients (biologicals and chemicals) are defined in terms of origin and purity.
Does not mean that ingredients are 100% pure. For example, formulation
may contain bovine serum albumin (BSA), whose purity is >95% with 5%
unknown composition.
Serum-free
Good Manufacturing
Practice (GMP)
Refers to the current GMP (cGMP) regulations requiring manufacturers,
processors and packagers to take the necessary steps to ensure that their
products are traceable, safe, pure and effective.
When associated with a product or material, this term denotes that the product
has been prepared under some or all of the cGMP requirements to ensure
proper design, monitoring and control of the manufacturing processes,
facilities and the final product. cGMP regulation can be considered under a
phased approach, depending on the phase and intended use of a product
within a clinical application [8,9].
Intended use statements on product documentation should be reviewed by all
users. Intended uses of GMP products vary and are not necessarily qualified
or intended for applications outside of “research use only.”
Regional differences exist, where some national regulatory agencies provide
GMP certificates to manufacturers of GMP AMs and others do not provide
them.
Term is universally recognized by regulatory authorities.
cGMP
Manufactured under
GMP
GMP-compliant
GMP-grade
Compliant to 21 CFR
210, 211, 820
(continued)
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Table 1. Continued
Term Meaning
Alternative or
synonymous terms
Home-brewed A term used by AM end-users or manufacturers to describe products or
materials prepared or manufactured in-house. Processes and components are
generally not defined.
Laboratory-grade A term used by AM manufacturers to describe products or materials that are
intended to be used within the laboratory or for research use and not intended
for food, drug or medicinal/clinical use.
Research grade
Research use only
Laboratory use only
Non-pharmaceutical–
grade
Drug master file (DMF) Confidential document that contains chemistry, manufacturing processes and
controls for a product.The intention of a master file is to protect the
intellectual property of a material or product.
Information contained may be used to support regulatory submissions but does
not guarantee that it will be accepted for use on submission to regulatory
authorities.
Master file type varies, based on region. For example, in the United States, the 4
most common types of DMFs are:
• Type I: Manufacturing site, facilities, operating procedures, and personnel
• Type II: Drug substance, drug substance intermediate, and material used in
their preparation, or drug product
• Type III: Packaging material
• Type IV: Excipient, colorant, flavor, essence or material used in their
preparation
Regional differences in terminology exist. Drug master file is not used by
European regulators; for example; “master file” is synonymous with this term in
Europe.
Master file (EU)
Regulatory support file
(EU)
Protein-free A term used by AM manufacturers to describe products or materials that do not
contain proteins or polypeptides as ingredients.
May contain free amino acids, dipeptides, tripeptides and peptides (up to 20
amino acids).
Research use only
(RUO)
A term used by AM manufacturers to describe the intended use of materials
generally limited for use in research or pre-clinical applications only and not
for use in clinical trials unless qualified appropriately and approved for use in
a given application by applicable regulatory authorities.
RUO products may be manufactured under various quality management
systems, including ISO-certified or GMP.
Laboratory use only
Research-grade
Non-pharmaceutical–
grade
Laboratory-grade
Serum-free A term used by AM manufacturers to describe products or materials that do not
contain serum or plasma as an ingredient.
May contain ingredients that are processed or derived from blood, serum or
plasma such as albumin, transferrin, low-density lipids, hormones and platelet
lysate.
May contain other undefined ingredients that are not serum or plasma (eg,
tissue extracts such as bovine pituitary extract, platelet lysate, growth factors,
hormones and carrier proteins).
Serum-free media (SFM) allows researchers to grow specific cell types or
perform specific applications in the absence of serum.
Defined media
TSE/BSE-free Declaration that products or materials are fully chemically synthesized or free
from transmissible spongiform encephalopathy (TSE) and bovine spongiform
encephalopathy (BSE) risk materials.
Country of origin of material or product is important in assessing BSE/TSE risk,
because some countries are categorized by theWorld Health Organization for
Animal Health (OIE) as BSE-negligible risk or controlled for BSE risk.
Testing for BSE/TSE on raw materials does not currently exist.
The term is universally recognized by regulatory authorities.
Xeno-free (XF) A term used by AM manufacturers to describe products or materials that do not
contain ingredients derived from non-human animals. May contain
ingredients derived from human sources.This can include purified and
processed materials as well as undefined or unprocessed materials.
Recombinant materials should have human genetic DNA sequences; non-
human animal DNA sequences are not allowed. Plant, bacterial or yeast DNA
sequences are allowed.
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suppliers are not able or willing to disclose confiden-
tial yet necessary information despite vigilant due
diligence byAM users. Recognizing this dilemma,many
regulatory agencies allow suppliers to submit confi-
dential manufacturing information directly to the
agencies in the form of a master file. Master files are,
however, neither necessary nor required. With the
United States used as an example, a device or drug
master file (DMF) for a specific AM can be submit-
ted to the US Food and Drug Administration (FDA)
by the supplier, which users can then reference in their
regulatory submissions upon obtaining permission from
the DMF owner (ie, the supplier). Yet, a common
misunderstanding is that a master file represents reg-
ulatory approval for the use of that material. It is
important to recognize that master files are not re-
viewed by regulators unless they are cross-referenced
under an application for initiation of a clinical trial,
such as an investigational new drug (IND) applica-
tion in the United States or a clinical trial authorization/
application (CTA) in Europe or Canada, respectively.
In the United States, similar misunderstanding exists
with FDA 510(k)-cleared AMs. A 510(k)-clearance
covers only a very specific intended use and does not
guarantee that the AM is approved or safe for use in
all applications. No matter how an AM is labeled
(GMP, ACF, etc) or whether a master file or previ-
ously existing clearance exists, it is the responsibility
of the AM user to evaluate and qualify each AM for
use in a given application. Such risk-based qualifica-
tion plans are discussed in the following sections.
Regulation
Although there are regulations that describe both
quality and regulatory requirements for the manu-
facture of cellular therapies, the regulations do not
specifically describe quality requirements for AMs.They
do, however, provide a framework for strategies to
control these starting materials. Guidance on raw ma-
terial use (and hence AM use) is available from several
national and international organizations, including the
US FDA [3], the International Conference on Har-
monization (ICH) [4], the International Organization
for Standardization (ISO) [10], and the European
Medicines Agency (EMA) [5]. However, it should be
noted that guidance applied to traditional medicinal
products, such as small molecules, and biologic drug
product, such as blood or blood products, does not
translate directly to cellular therapeutics. We antici-
pate that regulations and minimum standards specific
to AMs will come with the maturing of the regener-
ative medicine industry, with the prediction that AMs
manufactured and maintained under quality systems
compliant to the relevant cGMP regulations will be
required at some point. In the interim, the following
examples of regulatory documents specific to raw ma-
terials that are recognized globally will serve as starting
points for evaluating, selecting and qualifying AMs:
International conference on harmonization
• ICH Q5A/D:Quality of biotechnological products
• ICH Q5E: Comparability of biotechnological/
biological products subject to changes in their
manufacturing process
• ICH Q6B Specifications:Test procedures and ac-
ceptance criteria for biotechnological/biological
products
• ICH Q7: Good Manufacturing Practice Guide
for Active Pharmaceutical Ingredients
• ICH Q8 (R2): Pharmaceutical development
• ICH Q9: Quality risk management
• ICH Q10: Pharmaceutical quality system
ISO (evaluation and selection of suppliers)
• ISO 9001: Quality Management Systems:
requirements
• ISO 13485: Medical Device Quality Manage-
ment System: requirements for regulatory
purposes
More common than global regulations are national
regulations and guidances brought forth by local reg-
ulatory authorities or partner organizations. As an
example, a sampling of available region-specific guid-
ance is presented here.
United States (FDA,USP)
In the United States, AMs used in the manufacture
of cellular therapeutics are subject to different levels
of regulations depending on whether the products are
minimally or more than minimally manipulated. Al-
though more-than-minimally manipulated tissue
products may use a variety of complex AMs as com-
pared with minimally manipulated tissue products, the
safety and compliance requirements for the AM are
the same for both types of products and are re-
quired to meet their applicable regulations. Depending
on the intended use of the final product, they may also
be subject to the quality systems associated with drugs
[11,12], biologics [13], and devices [14]. Here is a
summary of applicable regulations:
• 21 CFR 210 and 211 Current Good Manufac-
turing Practice (drugs)
▸ 11 CFR 211.80: Current Good Manufactur-
ing Practice for finished pharmaceuticals:
components and containers/closures
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▸ 21 CFR 211.110: Current Good Manufactur-
ing Practice for finished pharmaceuticals:
control of in-process materials
• 21 CFR 610.15: General biologicals products
standards: constituents materials
• 21 CFR 820 Quality system regulation (devices)
• 21 CFR 1271.210: Human cells, tissues sup-
plies and cellular and tissue-based products:
supplies and reagents
In addition to these regulatory documents, the United
States Pharmacopeia Convention (USP) publishes a
number of general chapters that define necessary
qualification activities for common AMs used in the
manufacture of cellular therapies [15,16]. Further USP
informational chapters provide guidance on a selec-
tion of regulatory requirements and propose
qualifications programs and risk-based approaches for
the qualification of AMs [3,8]. Despite being US-
centric, USP guidance is recognized and used globally
within the cell therapy industry. The following is a
summary of the USP compendial and general chap-
ters that are directly applicable to cellular therapy
products:
• <90> Fetal bovine serum quality attributes and
functionality tests
• <92> Growth factors and cytokines used in cell
therapy manufacturing
• <1024> Bovine serum
• <1027> Flow cytometry
• <1043> Ancillary materials for cell-, gene- and
tissue-engineered products
• <1044> Cryopreservation of cells
• <1046> Cellular- and tissue-based products
• <1047> Gene therapy products
Outside of the United States, there is recognition of
the need to set up quality requirements for these raw
materials, but the guidance on the regulatory require-
ments for AM manufacture and use in some regions
are less well developed. The following is a snapshot
of what currently exists in other regions.
Europe (EP/EDQM/EMA)
Ancillary materials are referred to as raw materials in
the EU.The following are a selection of EU-specific
documents that provide general guidance for the use
of AMs:
• British Standards Institution. PAS 83:2012 Guid-
ance on codes of practice, standardized methods
and regulations for cell-based therapeutics
• Directive 2004/23/EC Quality and safety for the
donation, procurement, testing, processing,
preservation, storage and distribution of human
tissues and cells
• Guideline on the risk-based approach accord-
ing to annex I, part IV of directive 2001/83/EC
applied to advanced therapy medicinal prod-
ucts (2013)
• Regulation (EC) No. 1394/2007, advanced therapy
medicinal products regulation
• Commission Directive 2009/120/EC amending di-
rective 2001/83/EC relating to medicinal products
for human use as regards advanced therapy me-
dicinal products
• Eudralex Volume 4: Good Manufacturing
Practices
• Eudralex Volume 4: Good Manufacturing
Practice Annex 2: Manufacture of biological
active substances and medicinal products for
human use
• Eudralex Volume 4, Good Manufacturing Prac-
tice Annex 13: investigational medicinal products
• CHMP Guideline on Human Cell-Based
Medicinal Products: 2008 EMEA/CHMP/
410869/2006
• EMA/CAT/GTWP/671639/2008, Guideline on
quality, non-clinical and clinical aspects of me-
dicinal products containing genetically modified
cells
Australia (TGA)
Like other regions, regulatory guidance for the use
of AMs within Australia is limited [17]. There is no
specific mention regarding the use of AMs within
relevant codes. The Therapeutic Goods Administra-
tion (TGA) governs the manufacture of cellular therapy
products within Australia, and guidance exists for
organizations who undertake the collection, process-
ing, testing, storage, release and quality assurance of
cellular therapy products [18]. Furthermore, Austra-
lian regulatory guidelines for biologicals exist outlining
a regulatory framework for human cell- and tissue-
based products under a specific group called
biologicals. These guidances place cellular therapy
products into one of four classes of biologicals with
the use of a risk-based approach that is dependent
on the methods used to prepare and process the
cellular therapies during manufacture and whether
the intended use is the same as their usual biological
function. As in other regions, reference to USP guid-
ance is further recommended when developing cellular
therapies. Interestingly, approval by the TGA is not
required to conduct phase I clinical trials in Austra-
lia. However, consideration must be given to the
safety of the cellular therapy product, inclusive of
the AMs used. It is required that cell products used
in clinical trials beyond phase I have been evaluated
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for safety, and removal of AMs must be adequately
demonstrated.
Japan (PMDA)
In Japan, the Pharmaceuticals and Medical Devices
Agency (PMDA) with the Ministry of Health, Labour
andWelfare (MHLW) are responsible for governing
the use of cellular and tissue-based products. At this
time, the regulatory framework is regulated by the Phar-
maceutical Affairs Law under the PMDA, and there
are published guidelines on the use of cellular- and
tissue-based products derived from processed cells and
tissues only. These applicable guidelines are cap-
tured under the following standards:
• Standards for biological ingredients (MHLWNo.
210, 2003)
• Standards for manufacturing and quality control
for medical device and in vitro diagnostic re-
agents (MHLW No. 169, 2004)
• General principles for the handling and use of
cellular/tissue-based products (MHLW No. 266,
2001)
• Guidelines on ensuring quality and safety of prod-
ucts derived from processed cell/tissue (MHLW
notifications: autologous No. 0208003, allo-
genic No. 0912006, 2008)
• Guidelines on ensuring the quality and safety of
products derived from processed human stem cells
(MHLW No. 1314, 2000)
• Points to consider on manufacturing and quality
control (MHLW notification No. 0327025, 2008)
Recently, the PMDA has established a scientific board
under the Office of Cellular andTissue-Based Prod-
ucts to further advance the regulatory aspects and
support the PMDA to evaluate cellular and tissue-
based therapies.This high-level consultative body will
be responsible for making recommendations on policy
for innovative products, providing regulatory guid-
ance and ultimately will develop regulations relating
to cellular- and tissue-based products, along with phar-
maceuticals, medical devices and biological products.
To conclude, although some of the above guid-
ances provide information on the eligibility of raw
materials and AMs used in the processing of cellular
therapy products, no actual regulation currently exists
that specifically outlines the regulatory requirements
for the use of AMs.There are, however, a number of
consistencies between regional and international guid-
ances. In general, various regulatory agencies
consistently recommend using the highest grade of AM
available that performs as required in a given appli-
cation (with no stipulation on minimum-grade AM
at present); following a risk-based approach to AM
qualification; conducting appropriate testing to dem-
onstrate AM removal from the final cell product; and,
ultimately, that the final cell product should be safe
and effective.
Compliance
In general terms, “compliance” means conforming to
a rule, such as a regulation, policy, standard or law.
However, in an industry in which no standard regu-
lations exist, it becomes vital to prioritize patient safety
above all else and to work with individual stakehold-
ers to define applicable compliance requirements for
applications on a case-by-case basis. Ultimately, patient
safety is the responsibility of regulators who work with
AM users or sponsors of an investigational or com-
mercialized product. However, regulators generally hold
the users responsible for working with their suppli-
ers of all reagents and materials to ensure that the
compliance requirements defined by their regulatory
authority have been met.
Although there are similarities between cell therapy
products, blood products and drug products, there are
still several areas of science and regulation that do not
easily translate between these industries. For example,
materials used in the manufacture of a pharmaceu-
tical drug product can generally be identified through
advanced analytical test methods and thus demon-
strated to be effectively removed from the final product
through such testing. By nature, pharmaceutical prod-
ucts can be manufactured in bulk, stored and then
analyzed before release. In contrast, cell products are
generally prepared in small batches and require ma-
terials that are biological in nature in the manufacturing
process. Few robust and sensitive analytical methods
exist to detect biological AMs, making it difficult to
differentiate from the biological cell product itself and
hence demonstrate definitive removal of the AM from
the final cell product [18]. The biological nature of
many AMs also presents challenges when attempt-
ing to validate the limit of tolerance and the limit of
detection along the cell therapy product develop-
ment path. Further adding to the dilemma is a general
lack of time available for long-term testing, as many
cell products are highly labile, cannot be terminally
sterilized and are intended to be administered imme-
diately after ex vivomanipulation to the patient.These
factors and others introduce inherent risk into cell
therapy products, adding to the need for consistency
around the quality claims, compliance and the need
for standards governing this industry.
Regulators often require the user to demonstrate
how inherent risk of materials used to manufacture
cell products will be mitigated. The ICH and USP
provide useful and well-recognized frameworks that
can be used to develop risk assessment and qualification
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plans to effectively evaluate AMs [3,19].The level of
qualification varies, depending on the amount of in-
herent risk associated with their composition, quality
and intended use. For example, a GMP AM devoid
of animal components (commonly labeled as animal-
derived component–free) would require less
qualification than a non-GMP reagent containing
animal components. However, the conundrum is that
many AMs used in the manufacture of cell-based prod-
ucts are inherently high–risk, and alternative low-
risk AMs commonly do not exist or perform
inadequately in a given application. One such example
is the transition from serum-containing cell culture
medium to animal-derived component–free or chem-
ically defined medium to minimize risk of adventitious
agent transmission. However, not all cell types can be
easily adapted to serum-free medium and may result
in a reduced yield of cells after expansion or a final
cell population that lacks the therapeutic benefits of
the earlier cells expanded in serum-containing medium.
As such, the combined goal of regulators, suppliers
and users alike is to minimize risk to patients by ef-
fectively evaluating and controlling each material or
reagent used during the cell product development
process.
Qualification
Similarly to all raw materials and starting materials,
AMs must be qualified to varying extent on the basis
of five key factors: source, purity, identity, safety and
suitability, which are outlined in several regulations,
guidances and draft guidances [3,5,6,11]. However,
the level of detail surrounding the qualification plan
depends on the intended application and the clinical
phase in which the cellular therapy product will be used
[9]. It is imperative to note that there is a cost asso-
ciated with AM qualification activities that must be
considered by both the user and the supplier. Cur-
rently, the demand for AMs for clinical applications
is limited, but it is growing as the number of clinical
trials increases and trials advance to later phases.There-
fore, historically, when there has been little incentive
for suppliers to increase compliance, suppliers are now
accelerating efforts to meet this market demand.
Further supporting this transitional period as the field
moves to include more standardization, regulators have
commonly been willing to work with users one-on-
one throughout the AM qualification process to provide
feedback on the proposed use of materials originally
intended for research use only.
Information pertaining to AM qualification ac-
tivities is typically included in regulatory submissions
for clinical trials, such as in IND applications (United
States) and CTA applications (EU, Canada) by a cell
product manufacturer, and accountability for all qual-
ification and risk assessment activities related to the
AM falls on the user.To aid in this process, the user
should establish early dialogue with regulators and the
AM suppliers to create appropriate compliance re-
quirements and product acceptance criteria, especially
in light of the inconsistencies in AM labeling, and
the high cost and limited availability of clinically
approved or higher compliant AMs. Table 2
Table 2. User and supplier accountabilities for ancillary material use.
Qualification activity Supplier User
Performance in the intended application X
Provide CoA, CoC, CoO for AM X
Verify country of origin to assure AM is safe with respect to source-relevant animal diseases (eg, BSE/TSE) X X
Conduct a risk assessment for use of AM, based on information provided by supplier, or in collaboration with the
supplier, for example, failure modes and effects analysis
X
Establish and implement qualification plan for AM X
Confirm CoA test results critical to the cell product (eg, functional assay) X
Characterization testing of AM and set specifications (eg, identity, purity, functionality, viral contamination,
animal origin, etc)
X X
Assess effect of lot-to-lot variation of AM on the final cell product X
Determine if biocompatibility, biodistribution, cytotoxicity or adventitious agent testing is needed (or testing
results might be available from supplier, if applicable)
X
Assess presence of residual AM in the final cell product X
Assess stability of AM X X
Qualify the supplier of the AM (eg, supplier audit) X
Execute quality and supply agreement X X
Implement higher manufacturing standards, custom formulation or replacement of substandard components X X
Upgrade manufacturing process for AM under cGMP compliance (ie, in some instances, there may be
requirements for shared costs and risk)
X X
Inform the user of any changes in the manufacturing process of the AM or design/formulation of the AM (eg,
under a quality agreement)
X
Prepare and submit a master file for AM, if applicable X
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summarizes some of the key accountabilities and re-
sponsibilities pertaining to AM qualification. It is
important to note, however, that required qualifica-
tion activities may be unique to each AM and global
region and activities noted in the table may not be fully
inclusive of these requirements.
The primary activity surrounding AMs is evalu-
ation of their performance and identification of AMs
that best perform in the intended application. Devel-
opment of an optimal protocol is typically initiated
in later stages of basic research with further refine-
ment during pre-clinical studies and throughout early-
stage clinical trials. In some instances, only research-
grade reagents or materials may be available for the
intended application at the current time, and, as
such, the continuum of compliance of AMs must
parallel the succession from pre-clinical studies to
early-stage clinical trials to pivotal-stage trials. That
is, AM compliance must increase as clinical trials
advance. To ensure a successful continuum in com-
pliance, the earlier in the development process AMs
can be considered, the better. As such, as soon as
the most favorable AMs are identified, a risk assess-
ment should be conducted by the user in collaboration
with the supplier. Furthermore, clearly defining where
and how the AM is used in the clinical manufactur-
ing process will help to further define the risk level
of the AM. For example, an AM that is used far
upstream of the final cell product, such as a cell
culture medium used in the expansion of cells that
will be further differentiated and processed multiple
times, may impose less risk to the final cell product
than a wash buffer that will be used to wash cells
immediately before infusion. It is critical to keep in
mind that early development and clinical work typi-
cally focus on safety, whereas later-stage clinical and
commercialization efforts are geared toward consis-
tency. Although the standard for safety is the same
for both early and pivotal development efforts (ie,
consistent throughout the entire qualification process),
the specifications for the manufactured cell therapy
product and the AMs used for its production become
more stringent in terms of documentation, testing
and monitoring. This further amplifies the need for
evaluating risk early on.
Standard risk assessment tools, such as a failure
mode and effects analysis, can be used to assist with
evaluating the risks and the criticality associated with
use of the AM in the proposed application. As part
of the risk assessment, a robust AM qualification
plan must be developed and should include a de-
tailed list of risk mitigation activities surrounding
the use of the AM.The qualification plan should be
developed by the end user through the use of data
generated both in research and pre-clinical activi-
ties, such as AM lot-to-lot variability and the amount
of residual AM that may remain in the final cell
product, and using information available from the
AM supplier. For example, most AMs should come
with a Certificate of Analysis (CoA) or Certificate of
Conformance (CoC) to confirm that the product
meets the defined quality and performance stan-
dards that demonstrate lot-to-lot consistency and
outline what specific testing is conducted on the
AM by the supplier. However, for many AMs, such
as serum products, in which variability is inherent, it
often falls on the user to establish acceptance crite-
ria and minimum standards for each lot of material
that can be evaluated with the use of internally de-
veloped assays specific to their cellular products.
Further qualification activities may require a Certif-
icate of Origin (CoO) that outlines the origin of the
materials used to manufacture the AM itself. These
should specify what animal-derived materials were
used in the process (sometimes available for both
primary and secondary ingredients) and what testing
has been conducted on animal-derived materials (eg,
mycoplasma and adventitious viral testing). Addition-
al supplier documentation may include quality
management system certificates, quality question-
naires and access to a master file, if applicable. On-
site audits of the supplier’s manufacturing facility
may also be welcomed.
Dialogue between the user and supplier can help
identify issues that may hamper obtaining regu-
latory approval. Furthermore, building a relation-
ship between the user and supplier early on in the
AM qualification process will help establish effective
communication between parties so that information
critical to the AM review and approval process, such
as changes or enhancements to the AM manufactur-
ing procedure, formulation and compliance, are
transmitted to the user in a timely manner. It is also
important to note that the availability of higher-
compliance AMs will be driven by user demand,
but, in some cases, both the supplier and the user
may need to share both the cost and risk of increas-
ing product compliance. These are just some of the
challenges and risks associated with an industry that
is still developing. Table 3 outlines specific chal-
lenges faced by users relating to the qualification
and approval process for use of a specific AM. The
resolution identified has been deemed acceptable by
the governing regulatory agency in these instances
only. Resolutions may not be representative of all
applications. These case studies are provided as ex-
amples only. Each user must qualify and obtain
independent approval for their own cell manufactur-
ing process, including justification for use of all AMs.
Overall, the user is responsible for the quality of the
final cellular therapy product and thus must ensure
that the AM used during its manufacturing is
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Table 3. Case studies.
Issue Product type End-user concern Resolution
Human-derived
component in AM
product
Cell culture medium Concern with FDA
regulations on use of
human materials in
the manufacture of
human cell therapy
products; concern
about viral testing
and traceability of
donors.
Supplier provided product- and lot-specific CoA
and CoO.
Supplier provided CoO for human raw material
component in medium with information on
method of collection, compliance with regulatory
guidelines and adventitious agent screening
(because viral inactivation was not previously
conducted).
Supplier may provide FDA 510 (k) clearance letter
for media use as a class II device for human cell
tissue culture [this may not commonly be
available] or reference to the medium master file
previously submitted to the FDA.
Component labeled
“for research use
only”
Various reagents, such
as cell culture
medium and cell
selection reagents
Concern regulatory
authorities would not
allow use of material
labeled “for research
use only” in the
clinical cell
manufacturing
process.
User worked with AM supplier to obtain details
regarding materials of construction,
manufacturing, sterilization, and testing of the
component. Included relevant information within
end-user’s IND and BLA.
Following relevant regulations and guidelines
applicable for medical devices, user tested the
component to ensure it met applicable standards
and demonstrated the component is suitable for
use in the cell therapy manufacturing process.
User also qualified the supplier, implemented
incoming material testing and maintained
continued oversight of the supplier as part of
their supplier qualification and monitoring
program.
User executed a quality agreement within their
supply agreement with the supplier to ensure
end-user’s quality requirements are met and
appropriate controls are in place for the AMs.
The approach was acceptable for use of the RUO-
labeled AM in early-stage (phase I/II) clinical
trials. Use of RUO-labeled product for late-stage
trials and commercialization is yet to be
determined.
DMSO (dimethyl
sulfoxide)
compatibility with
packaging
Liquid medium for
storage of frozen cells
Concern with placing
cell product having
DMSO into bag and
potential leachables
and extractables.
Supplier provided bag validation guide.
Supplier provided leachables and extractables
report and chemical resistance report with bag
film material compatibility to DMSO.
Supplier provided FDA 510(k) clearance (FDA)
and CE mark approval letter (EMA) for bag film
material use as part of a class II device for
storage of hematopoietic stem cells.
Use of antibiotics in
culture media
Antibiotics penicillin/
streptomycin in
culture media
FDA raised issue with
the presence of
antibiotics in culture
media and potential
for allergic reactions.
Proposed including antibiotics in initial primary
culture of mesenchymal stem cells with
subsequent passage in media without antibiotics.
In addition, validated washing of the final cell
product to ensure adequate removal of the AM
from the cell product before infusion.
Use of collagenase to
digest tissue
Enzymes FDA raised concern
about bacterial origin
and endotoxin levels.
FDA advised that if a safer alternative to
collagenase is available, that should be used first.
If not, only cGMP collagenase can be used in
clinical applications.
User needed to evaluate alternatives, and none
were found. End-user needed to ensure that no
residual collagenase was present in final cell
product.
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appropriate for use in the proposed application and
satisfies the regional regulations.
Conclusions
To consolidate a global perspective on the use of AMs
is challenging and constantly changing as the result
of ongoing review by many stakeholders. As de-
scribed throughout this paper, available information
from regional and international committees, associa-
tions and regulators only provides guidance and
emphasizes discretion, such as using a risk-based ap-
proach with consideration given to the direct effect
on the quality and safety of the cellular therapy product.
Nevertheless, it is clear that the removal of AMs within
a cellular therapy process must be demonstrated
through appropriate testing to indicate minimal or no
AM presence in the final cell product. All literature
sources consistently emphasize that all materials and
reagents that come in contact with the cell product
must be appropriately defined and controlled. Com-
monly, guidances include recommendations that the
highest grade, preferably GMP or pharmacopeial-
grade, AM should be used when possible, but that all
materials, regardless of quality or compliance, must
undergo a risk assessment and subsequent robust qual-
ification in the context of the intended application.
What can be gleaned from previously published lit-
erature and opinions of the cell therapy community is
that further consistency and standardization within the
cell therapy industry, and specifically regarding AMs,
is wanted and required.There are a number of global
harmonization initiatives that apply to AMs but are
broader-ranging than merely AM regulation and guid-
ance, such as by the Pharmaceutical Inspection
Convention and Pharmaceutical Inspection Co-
operation Scheme, jointly referred to as PIC/S, with the
mission “to lead the international development, im-
plementation and maintenance of harmonized GMP
standards and quality systems of inspectorates in the
field of medicinal products.”This, and other ongoing
initiatives by the ICH and the Regulatory Harmoni-
zation Steering Committee, will further clarify common
misunderstandings surrounding compliance and quality
of AMs, although the possible implementation of a
common global AM standard will be challenging and
is yet to be seen.There are also efforts by advocacy or-
ganizations such as the Alliance for Regenerative
Medicine and the International Society for Cellular
Therapy that have organized global working groups and
committees to continue to solicit feedback from the cell
therapy community and work with governing bodies
to facilitate the advancement of cellular therapies, which
includes standardization efforts and consolidated ap-
proaches to cell therapy manufacturing around the
world.This white paper is one such initiative.
There are still many challenges related to AMs in
the development of cell therapeutics, but we are start-
ing to see trends to reconcile these challenges.
Challenges faced by AM users, such as extensive and
expensive qualification activities, are being mitigated
by suppliers who are steadily increasing compliance
and, thus, reducing the inherent risk by transitioning
from materials containing animal-derived compo-
nents to animal component–free and chemically defined
materials, manufacturing reagents under GMP, gen-
erating master files and registering AMs with local
regulatory agencies. Additional challenges have been
addressed through the continued flexibility and un-
derstanding of regulators during the clinical trial
application process regarding the use of wide-ranging
AMs that are available and cost-effective. Continued
review of regulatory submissions on a case-by-case basis
that are based on both data and common sense, open
dialogue on qualification activities for AMs between
users and regulators, and subsequent communica-
tion with suppliers all remain critical for further
advancement of AM development and increasing com-
pliance. Many of us have observed encouraging trends
along these lines with open communication between
regulators, users and suppliers occurring early in the
development process. This has almost certainly had
a positive impact on the incidence of applications being
approved. Additional challenges are being addressed
on an ongoing basis.These include, for example, the
development of analytical test methods and potency
assays for AMs that are biological in nature to assist
with key qualification activities assessing purity, iden-
tity, safety and even suitability.
Because the cellular therapy industry is rapidly
growing and starting to mature, specific guidances,
regulations, and standardization surrounding AMs and
their use at various aspects of the development process
are sure to arise. Regulation will provide clarity sur-
rounding the requirements and responsibilities of AM
users and suppliers, which may either foster or impede
commercialization efforts. Although clarity around the
use of AMs is required, we must ensure that effi-
cient and realistic regulations are set that allow cost-
effective yet safe, innovative cell product development.
We hope we have provided a basis for continued dis-
cussion between users, suppliers and regulators in the
cell therapy field and ultimately to help guide strat-
egies for AM use to facilitate the development and
commercialization of effective cell therapies globally.
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